Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 3.12
ARNA's Cash to Debt is ranked lower than
67% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. ARNA: 3.12 )
Ranked among companies with meaningful Cash to Debt only.
ARNA' s 10-Year Cash to Debt Range
Min: 0.46  Med: 7.47 Max: 11204.39
Current: 3.12
0.46
11204.39
Equity to Asset 0.33
ARNA's Equity to Asset is ranked lower than
82% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ARNA: 0.33 )
Ranked among companies with meaningful Equity to Asset only.
ARNA' s 10-Year Equity to Asset Range
Min: 0.07  Med: 0.57 Max: 0.98
Current: 0.33
0.07
0.98
F-Score: 2
Z-Score: -3.96
M-Score: -2.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -270.91
ARNA's Operating margin (%) is ranked lower than
64% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. ARNA: -270.91 )
Ranked among companies with meaningful Operating margin (%) only.
ARNA' s 10-Year Operating margin (%) Range
Min: -2405.23  Med: -306.19 Max: -28.18
Current: -270.91
-2405.23
-28.18
Net-margin (%) -241.89
ARNA's Net-margin (%) is ranked lower than
64% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. ARNA: -241.89 )
Ranked among companies with meaningful Net-margin (%) only.
ARNA' s 10-Year Net-margin (%) Range
Min: -2421.99  Med: -309.85 Max: -23.88
Current: -241.89
-2421.99
-23.88
ROE (%) -101.39
ARNA's ROE (%) is ranked lower than
80% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. ARNA: -101.39 )
Ranked among companies with meaningful ROE (%) only.
ARNA' s 10-Year ROE (%) Range
Min: -7209.86  Med: -54.75 Max: -3.29
Current: -101.39
-7209.86
-3.29
ROA (%) -29.34
ARNA's ROA (%) is ranked lower than
52% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. ARNA: -29.34 )
Ranked among companies with meaningful ROA (%) only.
ARNA' s 10-Year ROA (%) Range
Min: -201.16  Med: -28.27 Max: -3.2
Current: -29.34
-201.16
-3.2
ROC (Joel Greenblatt) (%) -108.74
ARNA's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. ARNA: -108.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARNA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -759.39  Med: -102.25 Max: -16.16
Current: -108.74
-759.39
-16.16
Revenue Growth (3Y)(%) 23.60
ARNA's Revenue Growth (3Y)(%) is ranked higher than
80% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ARNA: 23.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARNA' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -13.15 Max: 35.1
Current: 23.6
0
35.1
EBITDA Growth (3Y)(%) -27.30
ARNA's EBITDA Growth (3Y)(%) is ranked lower than
78% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. ARNA: -27.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ARNA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -70.3  Med: -17.00 Max: 74.6
Current: -27.3
-70.3
74.6
EPS Growth (3Y)(%) -29.50
ARNA's EPS Growth (3Y)(%) is ranked lower than
78% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. ARNA: -29.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARNA' s 10-Year EPS Growth (3Y)(%) Range
Min: -57.1  Med: -18.10 Max: 104.7
Current: -29.5
-57.1
104.7
» ARNA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ARNA Guru Trades in Q3 2014

Jim Simons 773,155 sh (+1248.02%)
Murray Stahl 45,000 sh (unchged)
Ken Fisher 11,000 sh (unchged)
» More
Q4 2014

ARNA Guru Trades in Q4 2014

Murray Stahl 45,000 sh (unchged)
Ken Fisher 11,000 sh (unchged)
Jim Simons 230,500 sh (-70.19%)
» More
Q1 2015

ARNA Guru Trades in Q1 2015

Paul Tudor Jones 15,806 sh (New)
Jim Simons 924,800 sh (+301.21%)
Ken Fisher 11,000 sh (unchged)
Murray Stahl 45,000 sh (unchged)
» More
Q2 2015

ARNA Guru Trades in Q2 2015

Jim Simons 1,666,800 sh (+80.23%)
Murray Stahl 45,000 sh (unchged)
Ken Fisher 11,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ARNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.26
ARNA's P/B is ranked lower than
64% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. ARNA: 6.26 )
Ranked among companies with meaningful P/B only.
ARNA' s 10-Year P/B Range
Min: 0.74  Med: 3.86 Max: 29.43
Current: 6.26
0.74
29.43
P/S 16.27
ARNA's P/S is ranked lower than
59% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. ARNA: 16.27 )
Ranked among companies with meaningful P/S only.
ARNA' s 10-Year P/S Range
Min: 7.58  Med: 23.00 Max: 106
Current: 16.27
7.58
106
Current Ratio 3.81
ARNA's Current Ratio is ranked lower than
53% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. ARNA: 3.81 )
Ranked among companies with meaningful Current Ratio only.
ARNA' s 10-Year Current Ratio Range
Min: 1.68  Med: 7.75 Max: 91.72
Current: 3.81
1.68
91.72
Quick Ratio 3.64
ARNA's Quick Ratio is ranked lower than
52% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. ARNA: 3.64 )
Ranked among companies with meaningful Quick Ratio only.
ARNA' s 10-Year Quick Ratio Range
Min: 1.68  Med: 7.75 Max: 91.72
Current: 3.64
1.68
91.72
Days Inventory 378.27
ARNA's Days Inventory is ranked lower than
90% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. ARNA: 378.27 )
Ranked among companies with meaningful Days Inventory only.
ARNA' s 10-Year Days Inventory Range
Min: 301.17  Med: 554.86 Max: 555.68
Current: 378.27
301.17
555.68
Days Sales Outstanding 39.46
ARNA's Days Sales Outstanding is ranked higher than
70% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. ARNA: 39.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARNA' s 10-Year Days Sales Outstanding Range
Min: 0.8  Med: 49.72 Max: 602.47
Current: 39.46
0.8
602.47

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 45.83
ARNA's Price/Net Current Asset Value is ranked lower than
93% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. ARNA: 45.83 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ARNA' s 10-Year Price/Net Current Asset Value Range
Min: 0.79  Med: 2.96 Max: 225.5
Current: 45.83
0.79
225.5
Price/Tangible Book 6.71
ARNA's Price/Tangible Book is ranked lower than
58% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. ARNA: 6.71 )
Ranked among companies with meaningful Price/Tangible Book only.
ARNA' s 10-Year Price/Tangible Book Range
Min: 0.62  Med: 2.97 Max: 25.66
Current: 6.71
0.62
25.66
Price/Median PS Value 0.70
ARNA's Price/Median PS Value is ranked higher than
73% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. ARNA: 0.70 )
Ranked among companies with meaningful Price/Median PS Value only.
ARNA' s 10-Year Price/Median PS Value Range
Min: 0.36  Med: 0.86 Max: 2.71
Current: 0.7
0.36
2.71
Earnings Yield (Greenblatt) (%) -16.90
ARNA's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. ARNA: -16.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARNA' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -18.55  Med: 610.95 Max: 30966.3
Current: -16.9
-18.55
30966.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:RN3.Germany,
Arena Pharmaceuticals Inc was incorporated in the state of Delaware in April 14, 1997, and commenced operations in July 1997. The Company is a clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing oral drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ, its internally discovered drug for chronic weight management in adults who are overweight with a comorbidity or obese, is its first and only drug approved for marketing by any regulatory agency. In June 2012, the U.S. Food and Drug Administration, or FDA, approved its internally discovered drug, BELVIQ, for chronic weight management in adults who are overweight with comorbidity or obese. The Company is engaged in commercializing BELVIQ in the United States and ultimately in additional territories, selectively advancing its drug candidates and discovering additional drug candidates. Its programs include: BELVIQ, for chronic weight management; APD811, an orally available agonist of the prostacyclin (IP) receptor, is an internally discovered investigational drug candidate intended for the treatment of Pulmonary Arterial Hypertension; Temanogrel, an orally available inverse agonist of the serotonin 2A receptor, is an internally discovered investigational drug candidate intended for the treatment of thrombotic diseases; APD334, an orally available agonist of the S1P1 receptor, is an internally discovered investigational drug candidate intended for the potential treatment of a number of conditions related to autoimmune diseases, including multiple sclerosis, psoriasis and rheumatoid arthritis; APD371, an orally available agonist of the cannabinoid 2 receptor, is an internally discovered investigational drug candidate intended for the treatment of pain; GPR119, represents pharmaceutical target for discovering orally available small molecule agonists for the treatment of type 2 diabetes. The Company's wholly owned subsidiary, Arena Pharmaceuticals GmbH, or Arena GmbH, granted Eisai Inc., and Eisai Inc.'s parent company, Eisai Co. Ltd. exclusive rights to commercialize BELVIQ in the United States. The Company competes successfully against these organizations, which include many large, well-financed and experienced pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies. The Company's research and development programs involve the controlled use of hazardous materials, chemicals, biological materials and various radioactive compounds. In the United States, the Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, US Environmental Protection Agency, California Environmental Protection Agency, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, the CSA and other federal, state or local regulations.
» More Articles for NAS:ARNA

Headlines

Articles On GuruFocus.com
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
(ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial Results Nov 16 2013 
WEEKLY CFO SELLS HIGHLIGHT: ZNGA, ARNA, JACK, TUMI, PANW Apr 07 2013 
comment on ARNA Mar 15 2013 
comment on ARNA Mar 02 2013 
WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC Oct 07 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 

More From Other Websites
Arena Pharmaceuticals to Present at the Wells Fargo 2015 Healthcare Conference Sep 03 2015
Arena Pharmaceuticals to Present at the Wells Fargo 2015 Healthcare Conference Sep 03 2015
M argaret Court Arena receives LEED Gold certification Sep 01 2015
Westaim Completes Arena Transactions Aug 31 2015
Westaim completes Arena Transactions Aug 31 2015
Arena's Cloud PLM Integrates With Kenandy's Cloud ERP Aug 27 2015
Arena Pharmaceuticals (ARNA) Rises: Stock Adds 5.7% in Session Aug 24 2015
ARENA PHARMACEUTICALS INC Financials Aug 20 2015
Arena Solutions Partners with GoodData to Create Arena Analytics Aug 18 2015
Arena-JOGMEC JV Approves a USD$2.7M-12,600 Metre Drill Program on Atacama Copper Project Aug 18 2015
Connected Philips LED lighting for the Allianz Arena: FC Bayern Munich kicks off the season with... Aug 13 2015
Medical Device Companies Embrace Arena's Cloud-Based PLM Solution Aug 11 2015
10-Q for Arena Pharmaceuticals, Inc. Aug 09 2015
Biotech Stock Mailbag: Controversial Stocks Revisited Aug 07 2015
Arena Pharmaceuticals 2Q Loss Narrower-Than-Expected - Analyst Blog Aug 06 2015
Edited Transcript of ARNA earnings conference call or presentation 5-Aug-15 9:00pm GMT Aug 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK